The SSTR2 status in NET tumor cells evaluated by immunohistochemistry has been reported to be associated with the therapeutic efficacy of SSAs in pancreatic NETs (PanNETs) [18,19] and acromegaly [20]. This evidence concerns the gene SSTR2 and pancreatic neuroendocrine tumor.